Michael R. Hodges
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Michael R. Hodges has a total of 37 co-authors. Here are the top co-authors by number of shared publications:
- Amy K. Patick
Amplyx Pharmaceuticals, San Diego, CA, USA
2 shared publications A. Chen
1 shared publicationA.K. Raney
1 shared publicationAbhijeet Jakate
Clinical Pharmacology, Pfizer Inc , New York, New York
1 shared publication- Amanda Nguyen
Novartis Institutes for BioMedical Research, Translational Medicine, East Hanover, NJ, USA
1 shared publication - Andreas Hein
Novartis Institutes for BioMedical Research, Biologics, Basel, Switzerland
1 shared publication
Latest Publications
- Top Cited PapersOpen Access
- 9 April 2025
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 81 (5) , e302-e309
Fosmanogepix for the Treatment of Invasive Mold Diseases Caused by Aspergillus Species and Rare Molds: A Phase 2, Open-Label Study (AEGIS)
Background: Fosmanogepix (FMGX) inhibits glycosylphosphatidylinositol anchored cell wall transfer protein 1, essential for anchoring mannoproteins to fungal cell wall, critical for host invasion. This Phase 2 study evaluated efficacy and safety of FMGX treatment in invasive mold diseases (IMDs) by Aspergillus spp. and rare molds in adults with limited treatment options. Methods: Participants (≥18 years) received FMGX 1000 mg intravenously (IV; 3-hour infusion) twice on Day 1 followed by 600 mg IV or 800 mg oral (optional from Day 4) once a day for ≤42 days. Key endpoints were all-cause mortality (Day 42) and Data Review Committee (DRC)-assessed global response (end of study treatment), adjudicated as success (complete or partial response) or failure (stable disease or progression of disease or death). Results: Of 21 participants enrolled (safety population), 20 were included in the modified Intent-to-Treat population (mean age: 61.9 years; females: 2 [10%]). Day-42 all-cause mortality was 25% (80% confidence interval [CI]: 12.7%—41.5%). DRC-assessed global response success rate was 40% (80% CI: 24.9%—56.7%). 258 adverse events (AEs) were reported (n = 21). 15 participants experienced 36 FMGX-related AEs, 2 had 3 serious AEs. Three participants (14.3%) discontinued study treatment due to FMGX-related AEs. Nine deaths (43%) were reported. One death was assessed as possibly related and unrelated to FMGX by the investigator and Data and Safety Monitoring Board, respectively. Conclusions: Safety profile was acceptable in high-risk patients with limited treatment options, supporting development of FMGX for treating IMDs caused by Aspergillus and rare molds. Clinical Trials Registration. NCT04240886; EudraCT number: 2019-001386-33.
- 9 April 2025
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 81 (5) , e302-e309
Top Cited PapersOpen AccessFosmanogepix for the Treatment of Invasive Mold Diseases Caused by Aspergillus Species and Rare Molds: A Phase 2, Open-Label Study (AEGIS)
Background: Fosmanogepix (FMGX) inhibits glycosylphosphatidylinositol anchored cell wall transfer protein 1, essential for anchoring mannoproteins to fungal cell wall, critical for host invasion. This Phase 2 study evaluated efficacy and safety of FMGX treatment in invasive mold diseases (IMDs) by Aspergillus spp. and rare molds in adults with limited treatment options. Methods: Participants (≥18 years) received FMGX 1000 mg intravenously (IV; 3-hour infusion) twice on Day 1 followed by 600 mg IV or 800 mg oral (optional from Day 4) once a day for ≤42 days. Key endpoints were all-cause mortality (Day 42) and Data Review Committee (DRC)-assessed global response (end of study treatment), adjudicated as success (complete or partial response) or failure (stable disease or progression of disease or death). Results: Of 21 participants enrolled (safety population), 20 were included in the modified Intent-to-Treat population (mean age: 61.9 years; females: 2 [10%]). Day-42 all-cause mortality was 25% (80% confidence interval [CI]: 12.7%—41.5%). DRC-assessed global response success rate was 40% (80% CI: 24.9%—56.7%). 258 adverse events (AEs) were reported (n = 21). 15 participants experienced 36 FMGX-related AEs, 2 had 3 serious AEs. Three participants (14.3%) discontinued study treatment due to FMGX-related AEs. Nine deaths (43%) were reported. One death was assessed as possibly related and unrelated to FMGX by the investigator and Data and Safety Monitoring Board, respectively. Conclusions: Safety profile was acceptable in high-risk patients with limited treatment options, supporting development of FMGX for treating IMDs caused by Aspergillus and rare molds. Clinical Trials Registration. NCT04240886; EudraCT number: 2019-001386-33.
- Open Access
- 10 July 2024
- Published by Elsevier in American Journal of Transplantation
- Vol. 24 (11) , 1994-2006
Nonclinical and clinical characterization of MAU868, a novel human-derived monoclonal neutralizing antibody targeting BK polyomavirus VP1
- 10 July 2024
- Published by Elsevier in American Journal of Transplantation
- Vol. 24 (11) , 1994-2006
Open AccessNonclinical and clinical characterization of MAU868, a novel human-derived monoclonal neutralizing antibody targeting BK polyomavirus VP1